APA (7th ed.) Citation

D, P., M, C., A, D., A, L., M, K., J, H., . . . L, L. (2026). Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. HemaSphere, 10(6), e70407. https://doi.org/10.1002/hem3.70407

Chicago Style (17th ed.) Citation

D, Pinkle, et al. "Complementary Efficacy of CD127-directed Immunotherapy with Lusvertikimab and ABL-targeting Tyrosine Kinase Inhibitors in Preclinical ABL-class-fusion-positive B-ALL." HemaSphere 10, no. 6 (2026): e70407. https://doi.org/10.1002/hem3.70407.

MLA (9th ed.) Citation

D, Pinkle, et al. "Complementary Efficacy of CD127-directed Immunotherapy with Lusvertikimab and ABL-targeting Tyrosine Kinase Inhibitors in Preclinical ABL-class-fusion-positive B-ALL." HemaSphere, vol. 10, no. 6, 2026, p. e70407, https://doi.org/10.1002/hem3.70407.